This analysis of COVIDENCE UK investigated potential sociodemographic, behavioural, clinical, pharmacological and nutritional determinants of antibody responses to administration of SARS-CoV-2 vaccination and booster doses. It was a pleasure to talk with Professor Adrian Martineau (Queen Mary University of London, London, UK) around the aims, methodology and patient population of the COVIDENCE UK study and to learn which determinants of antibody response were identified.
The abstract ‘Determinants of antibody responses to primary courses and booster doses of SARS-CoV-2 vaccines in 9,101 UK adults‘ (Abstract number: PA1116) was presented at ERS 2022, 4–6 September, 2022.
Questions
- Could you give us a brief overview of the COVIDENCE UK study and its achievements to date? (0:11)
- What is known about antibody responses to SARS-CoV-2 vaccination? (1:12)
- What were the aims, methodology and patient population of this study? (2:03)
- What determinants of antibody response were identified? (3:27)
- How can these findings be used to improve antibody responses to vaccination? (5:39)
Disclosures: Adrian Martineau discloses receiving grant/ research support from Barts Charity (ref. MGU0459), Pharma Nord Ltd, the Fischer Family Foundation, DSM Nutritional Products Ltd, the Exilarch’s Foundation, the Karl R Pfleger Foundation, the AIM Foundation, Synergy Biologics Ltd, Cytoplan Ltd, the UK National Institute for Health Research Clinical Research Network, the HDR UK BREATHE Hub, Thornton & Ross Ltd, Warburtons Ltd, Mr Matthew Isaacs (personal donation), and Hyphens Pharma Ltd; serving on advisory boards for Qiagen Ltd; and receiving honoraria from DSM Nutritional Products Ltd, Linus Pauling Institute.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
